HomeWhat is GSHArticlesFAQsContact Us

 

 

 

 

home > articles > cancer

Glutathione Articles - Cancer

  1. Cascinu S.; Catalano V.; Cordella L.; Labianca R.; Giordani P.; Baldelli AM.; Beretta GD; Ubiali E.; Catalano G, Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized double-blind, placebo-controlled trial. Jour. Clin. Oncol. 20(16); 3478-83 2002 Aug.

  2. Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG, Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small lung cancer. Wien Klin Wochenschr. 112(14); 617-23 2000 Jul.

  3. Smyth JF; Bowman A; Perren T; Wilkinson P; Prescott RJ; Quinn KJ; Tedeschi M, Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial. Ann Oncol. 8(6); 569-73 1997 Jul.

  4. Bernareggi A; Torti L; Facino RM; Carini M; Depta G; Casetta B; Farrell N; Spadacini S; Ceserani R; Tognella S, Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats anc cancer patients. J Chromatogr B Biomed Appl. 669(2); 247-63 1995 Jul.

  5. Cascinu S; Cordella L; Del Ferro E; Fronzoni M; Catalano G, Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy on advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 13(1); 26-32 1995 Jan.

  6. Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S, Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol. 55(1); 82-6 1994 Oct.

  7. Locatelli MC, D'Antona A, Labianca R, Vinci M, Tedeschi M, Carcione R, Corbo A, Venturino P, Luporini G, A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori. 1993 Feb 28; 79(1):37-9.

  8. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C, Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials.  Cancer Treatment Reviews (2007) 33, 407– 418.

  9. Pirovano C, Balzarini A, Bohn S, Oriana S, Spatti GB, Zunino F, Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Tumori. 1992 Aug 31;78(4):253-7.

  10. Friesen C, Kiess Y, Debatin K-M, A critical role of glutathione in determining apoptosis sensitivity  and resistance in leukemia cells. Cell Death and Differentiation. 2004;11:S73-S85.

  11. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F, Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathine protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol. 1990;25(5):355-60.

  12. Richie JP, Kleinman W, Marina P, Abraham P, Wynder EL, Muscat JE, Blood Iron, Glutathione, and Micronutrient Levels and the Risk of Oral Cancer.  Nutr Cancer. 2008;60(4):474-82.

 

     
 


Glutathione Experts | What is Glutathione (GSH)? | Glutathione Articles | GSH FAQs | Contact